First Pharmaceutical Holdings announced that the company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. As a candidate drug for fourth-generation ALK inhibitors, the clinical trial application for SY-12321 capsule single drug in advanced anaplastic lymphoma kinase positive advanced solid tumors was approved.

First Pharmaceutical Holdings announced that the company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. As a candidate drug for fourth-generation ALK inhibitors, the clinical trial application for SY-12321 capsule single drug in advanced anaplastic lymphoma kinase positive advanced solid tumors was approved.